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Summary
Wilms Tumor-1 (WT1) expression level is implicated in the prognosis of
acute myeloid leukaemia (AML). We hypothesized that a gene expression
profile associated with WT1 expression levels might be a good surrogate
marker. We identified high WT1 gene sets by comparing the gene expres-
sion profiles in the highest and lowest quartiles of WT1 expression in two
large AML studies. Two high WT1 gene sets were found to be highly corre-
lated in terms of the altered genes and expression profiles. We identified a
17-probe set signature of the high WT1 set as the optimal prognostic pre-
dictor in the first AML set, and showed that it was able to predict progno-
sis in the second AML series after adjustment for European LeukaemiaNet
genetic groups. The gene signature also proved to be of prognostic value in
a third AML series of 163 samples assessed by RNA sequencing, demon-
strating its cross-platform consistency. This led us to derive a 4-gene
expression score, which faithfully predicted adverse outcome. In conclu-
sion, a short gene signature associated with high WT1 expression levels and
the resultant 4-gene expression score were found to be predictive of adverse
prognosis in AML. This study provides new clues to the molecular path-
ways underlying high WT1 states in leukaemia.
Keywords: WT1, gene signature, expression score, AML, prognosis.
Acute myeloid leukaemia (AML) is a heterogeneous disease
with variable prognosis depending mainly on the underlying
genetic aberrations. AML patients are classified according to
different risk-stratification guidelines, including those of the
World Health Organization (WHO) (Swerdlow et al, 2008)
and the European LeukaemiaNet (ELN) (Dohner et al,
2010). These guidelines are mainly based on the presence or
absence of specific cytogenetic aberrations and gene muta-
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tions. However, the guidelines have evolved over the years,
as more and more new factors are found to affect AML
prognosis given our increasing knowledge of the AML biol-
ogy as well as the emergence of modern powerful high-
throughput tools, including gene expression profiling (GEP)
and next generation sequencing. Several studies have since
attempted to explore the correlation of biologically relevant
events to AML-GEP and prognosis using supervised cluster
analysis. These studies have led to identification of several
prognostic gene signatures related to various biological or
clinical characteristics, including gene rearrangements
(Camos et al, 2006; Wilson et al, 2006), gene mutations in
NPM1 (Verhaak et al, 2005), CEBPA (Wouters et al, 2009),
FLT3 (Neben et al, 2005) and WT1 (Becker et al, 2010), gene
expression (de Jonge et al, 2010), leukaemic stem cells (Gen-
tles et al, 2010) and drug sensitivity (Tagliafico et al, 2006).
High levels of WT1 expression were originally found to be
associated with poor prognosis in adult AML patients and used
as a marker for the detection of minimal residual disease in
AML (Inoue et al, 1994), as well as in acute lymphoblastic
(ALL) (Inoue et al, 1994) and chronic myeloid leukaemia
(CML) (Inoue et al, 1996). The predictive value of isolated high
WT1 expression in AML has been confirmed in several follow-
up long-term studies (Bergmann et al, 1997; Trka et al, 2002),
and it was in fact extended to therapy subgroups, including
haematopoietic stem cell transplantation (Jacobsohn et al,
2009), though it was not a consistent finding in this setting
(Ostergaard et al, 2004). However, despite numerous clinical
studies providing solid evidence for the role of high WT1 levels
in leukaemia, its role is not yet clearly defined in the context of
other known risk factors relevant for AML prognosis. More-
over, little is known about the molecular alterations associated
to highWT1 levels that can be responsible for its poor prognos-
tic impact. As a transcriptional regulator, WT1 binds to some
common DNA binding sites (Rauscher et al, 1990), and it is
not surprising that changes in its expression levels are associ-
ated with changes in the expression of hundreds of genes (Kim
et al, 2009; Vidovic et al, 2013). We hypothesized that high
WT1 expression was the sign of a true biological entity associ-
ated with a characteristic gene expression profile, and poten-
tially correlated to AML prognosis. We tested this hypothesis
by exploring the GEP differences among high- and low-express-
ing WT1 samples in two large AML series and next attempted
to predict AML outcome using a gene signature and a gene
expression score determined from high WT1 expression. This
can shed some light on the molecular mechanisms underlying
the role of highWT1 in AML pathogenesis as well as prognosis.
Methods and materials
Patients and samples
The first series of AML patients, hereafter called ‘Netherlands
series’, comprised 524 younger adult (≤60 years) cases who have
been treated according to sequential the Dutch-Belgian Hae-
mato-Oncology Cooperative Group and the Swiss Group for
Clinical Cancer Research (HOVON/SAKK) AML-04, -04A, -29,
-32, -42, and -43 protocols (Valk et al, 2004; de Jonge et al,
2010). The second series, hereafter called ‘Germany series’, con-
sisted of 562 adult AML patients who were enrolled in the Ger-
man AMLCG-99, AMLCG-M3, AMLSG AML HD98A or
HD98B trial protocols (Herold et al, 2014). The third series,
hereafter called The Cancer Genome Atlas series (‘TCGA series’),
consisted of 163 adult AML patients enrolled in Cancer and Leu-
kemia Group B (CALGB) treatment protocols 8525, 8923, 9621,
9720, 10201, and 19808 including those with survival and
immunophenotyping data (The Cancer Genome Atlas Research
Network, 2013). The Netherlands (GSE14468) and Germany
(GSE37642) gene expression sets were retrieved from NCBI Gene
Expression Omnibus (GEO), and the normalized RSEM (RNS
sequencing [RNA-Seq] by Expectation-Maximization) and clini-
cal AML data set (LAML) were obtained from the TCGA Data
Portal (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp).
Gene expression profiling
The Netherlands Study employed HG-U133 Plus 20 arrays
(Affymetrix, Santa Clara, CA, USA) for gene expression profil-
ing (Verhaak et al, 2009), while the Germany Study used either
HG-U133 Plus 20 or HG-U133A and U133B arrays (Affyme-
trix) (Li et al, 2013). For practical reasons, only common
probe-sets among two Germany subgroups were used in this
study. The normalized RSEM data obtained from RNA-seq
was used as an estimate of TCGA gene expression profiles.
High WT1 gene set
Each data series was separately sorted based on WT1 expres-
sion (using probe-set 206067_s_at), resulting in four quartiles.
The fourth quartile (Q4) of the samples with highest mean
WT1 expression was compared with the first quartile (Q1)
with lowest mean WT1 expression. Those probe-sets with sig-
nificant differential expression in Q4 as compared to Q1 were
considered as the high WT1 gene set for that AML series.
Statistical analysis
The two-tailed student’s t-test (IBM SPSS, v.20, IBM, Armonk,
NY, USA) was used to compare the means among Q4 versus
Q1 samples, with acceptable Benjamini false discovery rate
(FDR) of less than 005. Linear regression analysis (IBM SPSS,
v.20) was performed to study the correlation of the differences
among various gene sets. Overall survival (OS) was measured
from the date of patient enrolment to the date of death. Event-
free survival (EFS) was measured from the date of patient
enrolment to the date of failure to achieve complete remission,
relapse from complete remission or death. Relapse-free sur-
vival (RFS) was measured from the date of complete remission
to the date of relapse or death. Cox regression test (IBM SPSS,
v.20) was used for univariate and multivariate analysis of sur-
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vival in the classifier and validation AML series. Univariate
Cox regression analysis was performed using each of the
potentially implicated variables. Multivariate Cox regression
analysis was performed using all variables with P < 01 in uni-
variate analyses. Kaplan–Meier analysis was performed using
Mantel-Cox statistic (IBM SPSS, v.20) in order to test the equal-
ity of survival distributions for the different levels of the classi-
fier in both the classifier and validation AML series.
Outcome prediction
The online KNNXValidation tool (version 6) from GenePat-
tern suite (version 381; Broad Institute, Cambridge, MA,
USA) (Reich et al, 2006) was employed to predict the prog-
nostic gene signature, with EFS as the favourable event, and
all others (dead, no remission, progressive disease/relapse) as
adverse events. The Student’s t-test (median) was used to
select the probe-sets. The resultant predicting list was
trimmed so that only those probe-sets that repeated in at
least 90% of the permutations were kept. GENE-E (http://
www.broadinstitute.org/cancer/software/GENE-E/) was used
for supervised clustering of each AML series using trimmed
probe-set list or candidate gene signature.
Gene expression score
Receiver operating characteristic (ROC) curve analysis (IBM
SPSS, v.20) was performed for individual probe-sets of the
gene signature in order to assess their correlations to the EFS
in the Netherlands series. Expression scores were developed
for each sample using addition of the expression levels for
the top two significant probe-sets considering their positive
or negative correlation to the EFS. This was repeated after
inclusion of the progressively less significant probe-sets, giv-
ing rise to expression scores for the lists of 2–17 probe-sets.
The median expression scores were used to classify the sam-
ples into two groups, and their association to the EFS were
assessed using ROC curve analysis.
Pathway analysis
Pathway analysis was performed using GeneGo MetaCore
(https://portal.genego.com). In brief, the gene set was
uploaded to MetaCore and Functional Ontology Analysis was
performed to identify the enriched pathway maps. Build Net-
works Analysis was conducted to identify the Shortest Paths
among input genes.
Results
A high degree of correlation was found between the high
WT1 gene sets from two AML series
Normalized gene expression data were used to obtain differen-
tially expressed genes in high WT1 expressing samples. Com-
parison of the high WT1 (Q4) and low WT1 (Q1) samples in
the Netherlands series (Fig 1) identified 19 318 probe-sets as
differentially expressed (Table SI), including WT1 expression
level showing 103 fold difference. Likewise, 23 705 probe-sets
were found to be differentially expressed in high WT1 samples
in the Germany series (Table SII), including WT1 expression
level, which showed 164-fold difference. These probe-sets rep-
resented genes that were either positively or negatively corre-
lated with WT1 expression levels. About 62% of the probe-sets
in the Netherlands high WT1 gene set were also found in the
Germany high WT1 set, with 967% of them differing in the
same direction. Linear regression analysis showed a high
degree of correlation of the fold differences between the two
high WT1 sets (Fig S1). At the gene level, 57% similarity was
observed between the top 100 genes from the two high WT1
gene sets (Tables SI and SII).
A 17-probe set signature was found to be the optimal
predictor of prognosis in the Netherlands AML series
The workflow that was used for prediction training and valida-
tion is illustrated in Fig 1. Briefly, The Netherlands GEP limited
to the high WT1 set was used as a classifier by means of
KNNXValidation and EFS as the favourable event. GEP of the
AML samples were clustered using lists of 10 to 50 probe-sets as
predicted by KNNXValidation. Classification of the Netherlands
AML series using each predicted list identified a cluster of
patients with distinct GEP that was associated with high WT1
expression levels (Q4). This high WT1 cluster was found to be
associated with adverse prognosis, with a list of 17 probe-sets
(herein called S17 signature) as the optimal predictor of the
long-term prognosis in terms of both significance level and haz-
ard ratio (HR) (Fig S2). The S17 signature (Table SIII) classi-
fied a distinct cluster of patients (Fig 2A) associated with high
WT1 status [Odds ratio (OR) =30, P = 16 9 106] as well as
poor prognosis, with 5-year OS of 96% vs. 441% {HR = 272
[95% confidence interval (CI): 215–344]}, and 5-year EFS
of 61% vs. 377% (HR = 269 [95% CI: 210–344]) (Fig 2B–C,
Table SIV). The median OS and EFS for this cluster of patients
were 83 (95% CI: 67–99) and 49 (95% CI: 32–65) months
respectively, compared to 323 (95% CI: 1681–478) and 145
(95% CI: 94–195) months for others. Although the high WT1
cluster was also found to be correlated to other known risk fac-
tors including del(5q)/(7q), FLT3-internal tandem duplication
(ITD), WT1 status (positively), and inv(16), t(15;17), t(8;21),
FLT3-tyrosine kinase domain (TKD) and CEBPA (double muta-
tion) status (negatively) (Fig 2A), its prognostic impact
remained highly significant after adjustment for baseline charac-
teristics and known prognostic factors (Table I).
The S17 signature was an independent prognostic factor
in the Germany AML series
In order to validate the prognostic value of the S17 signature,
it was tested against the Germany series. Supervised
Prognostic WT1 Gene Expression Score in AML
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clustering of the Germany series using the gene signature
predicted a cluster of patients with a distinct GEP similar to
the Netherlands series (Fig 3A) and predicting both adverse
OS and RFS (Fig 3B–C, Table SV). The median OS was 76
(95% CI: 59–93) months for the cluster of patients with
high WT1 as compared to 139 (95% CI: 110–168) months
for other cases. Similarly, the median RFS was 53 (95% CI:
42–64) months for high WT1 cases as compared to 173
(95% CI: 134–212) months for the remaining patients. This
prognostic impact of the S17 signature remained statistically
significant after adjustment for baseline characteristics and
ELN genetic risk groups (Table II).
The S17 signature predicted adverse survival in the
TCGA AML series
We further tested the prognostic value of the high WT1 sig-
nature in the TCGA series, which showed a cluster of
patients with a similar distinct GEP (Fig 4A), predicting
adverse OS (Fig 4B). The median OS was 120 (95% CI:
101–139) months for the cluster of patients with high WT1
as compared to 191 (95% CI: 112–270) months for others.
No correlation was found between the high WT1 cluster and
gene mutations of prognostic significance, including FLT3-
ITD, NPM1, or IDH mutations. Immunophenotyping analy-
sis of the AML cells identified a positive correlation of the
high WT1 cluster with CD34+ (OR = 45, P = 0001) and
CD7+ (OR = 144, P = 003) cells.
An expression score based on top four genes predicted
adverse outcome in three AML series
ROC curve analysis ranked 17 probe-sets based on their cor-
relation to the EFS in the Netherlands series (Table SVI).
CD109 (226545_at) was the most significant gene and the
HAVCR2 (1555628_a_at) the least significant. A gene expres-
sion score derived from the cumulative expression levels of
the top four genes [CD109, KIAA0125 (also termed
FAM30A), NGFRAP1 and ZC3H12C], herein called W4,
demonstrated very high correlation to the EFS in the Nether-
lands series (Table SVII). The W4 genes were all overex-
pressed in the poor risk group. As anticipated, the W4 score
Fig 1. The workflow used to identify and validate the prognostic gene signature associated with high levels of WT1 expression. AML, acute mye-
loid leukaemia; GEP, gene expression profiling; OS, overall survival; EFS, event-free survival; RFS, relapse-free survival; TCGA, The Cancer Gen-
ome Atlas.
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predicted adverse outcome in the Netherlands series tested
by Cox regression analysis (Fig 5A), with a median OS of
109 and 855 months (P = 2 9 1014) in the high- and
low-W4 cases, respectively. Similarly, the median EFS was 80
and 267 months (P = 4 9 1013) in these groups (Fig 5B),
and remained statistically significant after adjustment for
baseline characteristics and known prognostic factors
(Table SVIII). The W4 expression score was also able to
(A)
(B) (C)
Fig 2. (A) Supervised clustering of the Netherlands acute myeloid leukaemia (AML) series using the S17 signature. The marked cluster of the
high WT1 comprising of 34% of the patients with AML showed distinct gene expression profiling as compared to the remaining clusters. This
cluster was found to be positively associated with del(5q)/(7q), FLT3-internal tandem duplication (ITD) and WT1 mutational status, whereas it
was negatively associated with inv(16), t(15;17), t(8;21), and CEBPA double mutation, with the latter markers creating distinct clusters. (B, C)
Kaplan–Meier analysis of the survival in the training Netherland series clustered by S17 signature. Log-Rank (Mantel–Cox) P-values included
44 9 1018 and 21 9 1016 for OS (B) and EFS (C), respectively. OS, overall survival; EFS, event-free survival;
Table I. Multivariate analysis of the OS and EFS in the Netherlands acute myeloid leukaemia series using Cox Regression analysis of those
variables which were significant at the level of P < 0.1 in univariate Cox Regression.
Variable
OS EFS
P-value HR
95% CI for HR
P-value HR
95% CI for HR
Lower Upper Lower Upper
S17 signature <0001 1852 1387 2473 <0001 1934 1465 2555
Age 0026 1121 1013 1239 NS - - -
Complex karyotype 0001 2198 1397 3458 0001 2182 1354 3518
del(5q)/del(7q) 0017 176 1109 2795 0001 2027 1322 3109
inv(16) 0027 0537 031 0931 0036 0569 0336 0964
t(8;21) 0010 0465 0259 0833 0004 0444 0254 0775
FLT3-ITD 0004 1526 1142 2037 0003 1548 1161 2062
NPM1-mutated 0001 0615 0456 083 0001 0603 0452 0804
CEBPA-double-mutated 0008 0397 0201 0785 0008 04 0203 0789
OS, overall survival; EFS, event-free survival; HR, Hazard ratio.
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predict adverse outcome in the Germany series. The median
OS was 85 and 245 (P = 2 9 1012) among the high- and
low-W4 cases, respectively, and the median RFS was 76 and
337 months (P = 3 9 1011) in these groups (Fig 5C, D).
This prognostic impact remained statistically significant after
adjustment for baseline characteristics and ELN genetic
groups (Table SIX). The positive predictive value (PPV) and
negative predictive value (NPV) of the marker for prediction
of adverse OS were 858% and 393%, respectively. They
were found to be 846% and 438%, respectively, for predic-
tion of adverse RFS. Finally, the W4 score was found to be
predictive of adverse OS in the TCGA series. The median OS
was found to be 110 and 260 months (P = 7 9 104)
among high- and low-W4 cases, respectively (Fig 5E). The
PPV and NPV of the marker for prediction of adverse OS
were 753% and 463%, respectively.
Pathway analysis
MetaCore pathway analysis of the Netherlands high WT1 set
of >2-fold difference identified Antigen Presentation by
major histocompatibility complex (MHC) Class II as the top
(A)
(B) (C)
Fig 3. (A) Supervised clustering of the Germany acute myeloid leukaemia series using the S17 signature. The marked cluster of the high WT1
patients, comprising 31% of the cases, showed distinct gene expression profiling as compared to the remaining clusters. (B, C) Kaplan–Meier
analysis of the survival in the Germany validation series clustered by S17 signature. Log-Rank (Mantel–Cox) P-values included 22 9 1013 and
54 9 1012 for OS (B) and RFS (C), respectively. OS, overall survival; RFS, relapse-free survival;
Table II. Multivariate analysis of the OS and RFS in the Germany AML series using Cox Regression analysis of the ELN genetic groups and those
variables which were significant at the level of P < 01 in univariate Cox Regression.
Variable
OS RFS
P-value HR
95% CI for HR
P-value HR
95% CI for HR
Lower Upper Lower Upper
S17 signature <0001 1485 1186 1860 <0001 1834 1326 2536
Age <0001 1291 1197 1391 <0001 1198 1081 1327
ELN2* <0001 2395 1743 3291 <0001 3147 2124 4663
ELN3* <0001 2395 1732 3312 <0001 2153 1405 3299
ELN4* <0001 3306 2376 4599 <0001 6401 4027 10175
OS, overall survival; RFS, relapse-free survival; HR, Hazard ratio.
*The ELN2, ELN3, and ELN4 indicate the corresponding genetic ELN groups compared to the ELN1 group, respectively.
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relevant pathway (Fig S3). Most of the pathway genes were
found to show low expression, indicating the downregulation
of the whole pathway. Likewise, Antigen Presentation by
MHC-II was found as the most biologically relevant pathway
in the Germany high WT1 set of >2-fold difference
(FDR = 85 9 103). MetaCore analysis of the S17 plus
WT1 identified a single dense network, indicating their fre-
quent interactions (Fig S4). Three canonical pathways were
identified, including those terminating on NFKB1, CREB1,
and MEF2 transcription factors. The upregulated HDAC4
seemed to be in a hub position for the network.
Discussion
Several studies have attempted to risk-stratify AML patients
using gene signatures obtained from GEP, though most of
these signatures were correlated with known risk factors and
hence of no further clinical benefit, including those associated
with mutations in NPM1 (Verhaak et al, 2005), double mutant
CEBPA (Wouters et al, 2009) and FLT3-ITD (Neben et al,
2005). Metzeler et al (2008) used an unbiased approach to
identify all genes whose expression levels were correlated to the
OS, which led to a prognostic score based on a 66-gene signa-
ture. More recently, Li et al (2013) conducted a similar global
study with more extensive training and validation steps
and identified a 24-gene signature that improved ELN risk
classification of AML. On the other hand, Becker et al (2010)
described a signature of 131 genes that was associated with the
WT1 mutation, though without any clinical impact.
We showed here that differentially expressed genes in high
WT1 samples were highly correlated in two AML series in
terms of altered genes, expression profiles and implicated
pathways, collectively corroborating the biological relevance
of the high WT1 gene signature. Hence, we inferred a 16-gene
signature using differentially expressed genes in high WT1
samples that was able to predict AML outcome in two inde-
pendent AML series. Although the S17 signature was also
associated with other known risk factors including some cyto-
genetic aberrations, FLT3-ITD and NPM1 status, as antici-
pated from a marker which is overexpressed in the vast
majority of AML samples (Ostergaard et al, 2004), it was also
predictive of clinical outcome independently of the currently
accepted ELN genetic groups (Dohner et al, 2010). This might
reflect the prognostic value of WT1 expression level in the vast
majority of AML patients regardless of their underlying
genetic risk factors (Bergmann et al, 1997; Trka et al, 2002).
WT1 mutation has been controversially reported to be asso-
ciated with adverse prognosis in AML (Virappane et al, 2008;
Gaidzik et al, 2009). We did not observe any prognostic
impact of WT1 mutation in the Netherlands series. However,
given the association of the WT1 mutation with the S17 signa-
ture, one cannot rule out the possibility of its indirect impact
through WT1 expression level. Given the growing list of gene
mutations of prognostic implication in AML, including
Fig 4. (A) Supervised clustering of the The Cancer Genome Atlas (TCGA) acute myeloid leukaemia (AML) series using the S17 signature. The
marked cluster of the high WT1 patients, comprising 36% of the cases, showed distinct gene expression profiling as compared to the remaining
clusters. (B) Kaplan–Meier analysis of the survival in the TCGA validation series clustered by S17 signature. Log-Rank (Mantel–Cox) P-value was
69 9 103 for OS.
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recently identified mutations in DNMT3A, TET2, and ASXL1,
a good surrogate marker can be a more global one, such as the
S17 signature, which is correlated to several markers, in addi-
tion to its independent impact. We also identified a CD34+-
CD7+ phenotype for high WT1 cluster of AML cells, which has
already been found to be associated with poor risk in AML
(Del Poeta et al, 1995) and possibly involved in clonal evolu-
tion of CML (Kosugi et al, 2005). However, the implication of
this finding needs further investigation.
Antigen Presentation by MHC Class II was found to be
the most relevant biological pathway in our study, which is
in line with findings of Wilson et al (2006), who demon-
strated that a cluster of AML patients with high WT1 expres-
sion also showed low expression of MHC-II genes. The fact
that targetable HDAC4 has been found to be a master regu-
lator of the S17 network might be of potential therapeutic
relevance [reviewed in (Tan et al, 2010)].
Finally, the S17 signature consistently predicted long term
outcome in different clinical settings, including age groups,
karyotype status and a wide variety of treatment regimens.
The S17 signature also demonstrated a similar prognostic
value in the much smaller series of TCGA-AML samples
assessed using a different GEP platform, i.e. RNA-seq, demon-
strating robust cross-platform predictive value. This was par-
ticularly promising, given that the RNA-seq gene expression
data show broad dynamic range (Zhao et al, 2014) and a very
high correlation to qRT-PCR results (Rapaport et al, 2013).
We hence attempted to derive a gene expression score using
the most significant genes amongst those included in the S17
signature. This led to the 4-gene W4 score, which faithfully
Fig 5. Kaplan–Meier analysis of the survival in
three acute myeloid leukaemia (AML) series as
stratified using W4 gene expression score. (A,
B) Survival analysis in the Netherlands AML
series. (C, D) Survival analysis in the Germany
series. (E) Survival analysis in The Cancer Gen-
ome Atlas series. OS, overall survival; EFS,
event-free survival; RFS, relapse-free survival.
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predicted the adverse outcome in the TCGA series tested by
RNA-seq, as well as the other two AML series examined by
microarray analyses. Therefore, the W4 score can be easily
used in a short AML series, or in its normalized form, as a sur-
rogate marker for the prognostication of AML patients on a
day-to-day basis. Among the W4 genes, CD109, which is also
found in the gene signature reported by Metzeler et al (2008),
is known to be expressed on a subset of haematopoietic stem
and progenitor cells (Lin et al, 2002) as well as activated plate-
lets and T-lymphoblasts (Sutherland et al, 1991), corroborat-
ing our immunophenotyping findings. CD109 overexpression
has also been observed in many human cancers (Hashimoto
et al, 2004). The other overexpressed gene, NGFRAP1, belongs
to the neurotrophin signalling pathway, of which many genes,
including NTRK1, NTRK2 and NTRK3, are known to be
implicated in leukaemogenesis (Eguchi et al, 1999; Meyer
et al, 2007; Li et al, 2009). To our knowledge, the W4 risk
score is the simplest gene expression score predicting long-
term AML prognosis (Gentles et al, 2010; Bou Samra et al,
2012; Marcucci et al, 2014).
In conclusion, we identified a short gene signature associ-
ated with high WT1 expression and demonstrated its adverse
and independent prognostic impact in adult AML patients. A
4-gene expression score was next derived, which similarly
predicted AML prognosis in the three series examined. Our
study proposes a novel way to incorporate a candidate prog-
nostic factor, i.e. WT1 expression level, into the current
models of AML risk stratification and provides new clues to
the molecular mechanisms underlying WT1 regulation. These
promising results will have to be validated in further trials.
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cumulative gene expression of the n most significant probe-
sets of the S17 to the EFS in the Netherlands series using
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